Skip to main content

Yesterday, Jan. 13, 2016, 39 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $6.56 to $2,760,975.00.

Highlighted Stocks Traded by Insiders:

Bazaarvoice (BV) - FREE Research Report

Offerdahl James, who is Chief Financial Officer at Bazaarvoice, bought 10,000 shares at $3.78 on Jan. 13, 2016. Following this transaction, the Chief Financial Officer owned 207,337 shares meaning that the stake was boosted by 5.07% with the 10,000-share transaction.

Austin Eugene, who is President at Bazaarvoice, bought 10,000 shares at $3.79 on Jan. 13, 2016. Following this transaction, the President owned 608,116 shares meaning that the stake was boosted by 1.67% with the 10,000-share transaction.

The shares most recently traded at $3.71, down $0.08, or 2.09% since the insider transaction. Historical insider transactions for Bazaarvoice go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 7,375
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 7,911
  • 24-Week # shares bought: 16,000
  • 24-Week # shares sold: 8,288

The average volume for Bazaarvoice has been 637,300 shares per day over the past 30 days. Bazaarvoice has a market cap of $302.5 million and is part of the technology sector and computer software & services industry. Shares are down 15.98% year-to-date as of the close of trading on Wednesday.

Bazaarvoice, Inc. operates as a network that connects brands and retailers to the voices of people where they shop. Currently, there are 3 analysts who rate Bazaarvoice a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BV - FREE

TheStreet Quant Ratings

Scroll to Continue

TheStreet Recommends

rates Bazaarvoice as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full

Bazaarvoice Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Walgreens Boots Alliance (WBA) - FREE Research Report

Lederer John Anthony, who is Director at Walgreens Boots Alliance, bought 10,000 shares at $81.00 on Jan. 13, 2016. Following this transaction, the Director owned 30,000 shares meaning that the stake was boosted by 50% with the 10,000-share transaction.

The shares most recently traded at $80.19, down $0.81, or 1.01% since the insider transaction. Historical insider transactions for Walgreens Boots Alliance go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 3,500
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 3,500
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 3,500

The average volume for Walgreens Boots Alliance has been 5.5 million shares per day over the past 30 days. Walgreens Boots Alliance has a market cap of $88.3 billion and is part of the services sector and retail industry. Shares are down 6.12% year-to-date as of the close of trading on Wednesday.

Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and wellbeing company. The company operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The stock currently has a dividend yield of 1.76%. The company has a P/E ratio of 19.9. Currently, there are 9 analysts who rate Walgreens Boots Alliance a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WBA - FREE

TheStreet Quant Ratings

rates Walgreens Boots Alliance as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Walgreens Boots Alliance Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

CombiMatrix Corporation (CBMX) - FREE Research Report

Burell Scott R, who is CFO, Secretary & Treasurer at CombiMatrix Corporation, sold 8,336 shares at $0.55 on Jan. 13, 2016. Following this transaction, the CFO, Secretary & Treasurer owned 24,471 shares meaning that the stake was reduced by 25.41% with the 8,336-share transaction.

McDonough Mark D, who is President and CEO at CombiMatrix Corporation, sold 21,552 shares at $0.55 on Jan. 13, 2016. Following this transaction, the President and CEO owned 53,790 shares meaning that the stake was reduced by 28.61% with the 21,552-share transaction.

The shares most recently traded at $3.11, up $2.56, or 82.37% since the insider transaction. Historical insider transactions for CombiMatrix Corporation go as follows:

  • 4-Week # shares bought: 20,500
  • 4-Week # shares sold: 21,244
  • 12-Week # shares bought: 455,500
  • 12-Week # shares sold: 21,244
  • 24-Week # shares bought: 455,500
  • 24-Week # shares sold: 21,244

The average volume for CombiMatrix Corporation has been 820,600 shares per day over the past 30 days. CombiMatrix Corporation has a market cap of $29.3 million and is part of the health care sector and health services industry.

CombiMatrix Corporation provides molecular diagnostic solutions and clinical support services. It offers DNA-based testing for the detection of genetic abnormalities.

Exclusive Offer: Get the latest Stock Analysis on CBMX - FREE

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.